Edward Mascioli
Directeur Général chez Matrivax Research & Development Corp.
Profil
Edward Mascioli is the founder of Dapis Capital LLC, which was founded in 2008.
He held the position of Managing Director from 2008 to 2010.
Currently, he is the President, Chief Executive Officer & Director at Matrivax Research & Development Corp.
and a Director at Mindset BioPharmaceuticals Ltd.
In the past, he was the Chief Executive Officer at Affinium Pharmaceuticals Ltd.
from 2013 to 2014, and the Chief Executive Officer at Karos Pharmaceuticals, Inc. He also held the position of Senior Medical Director at PAREXEL International Corp.
and was a Director at Arriva Pharmaceuticals, Inc., Radius Health, Inc., Elixir Pharmaceuticals, Inc., Oxagen Ltd., Gilead Connecticut, Inc., Sancilio & Co., Inc., Sancilio Pharmaceuticals Co., Inc., and Cardurion Pharmaceuticals LLC.
He was a Vice President at Pfizer Inc. from 2010 to 2012 and a Partner at SV Health Investors LLP from 2014 to 2016.
He was also a Venture Partner at MPM BioImpact, Inc. from 2001 to 2008 and a Vice President-Clinical Affairs at Peptimmune, Inc. He was a Member at Deaconess Hospital (Oklahoma).
Dr. Mascioli has a graduate degree from Massachusetts Institute of Technology, an undergraduate degree from Brandeis University, and a doctorate degree from the University of Massachusetts.
Postes actifs de Edward Mascioli
| Sociétés | Poste | Début |
|---|---|---|
Mindset BioPharmaceuticals Ltd.
 Mindset BioPharmaceuticals Ltd. Medical/Nursing ServicesHealth Services Mindset BioPharmaceuticals Ltd. develops disease modifying therapies. It specializes in molecular neuropharmacology, behavioral science, clinical neurology, drug delivery, and biopharmaceutical development. The company was founded by Daniel G. Chain in February 1997 and is headquartered in Jerusalem, Israel. | Directeur/Membre du Conseil | - |
Matrivax Research & Development Corp.
 Matrivax Research & Development Corp. BiotechnologyHealth Technology Matrivax Research & Development Corp. is developing human vaccines for the prevention and treatment of life-threatening bacterial diseases. Its pipeline includes two vaccine candidates implementing proprietary streptococcus pneumoniae and clostridium difficile protective antigens. The company was founded in October 2007 and is headquartered in Boston, MA. | Directeur Général | 01/03/2020 |
Anciens postes connus de Edward Mascioli
| Sociétés | Poste | Fin |
|---|---|---|
Cardurion Pharmaceuticals LLC
 Cardurion Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardurion Pharmaceuticals LLC is a cardiovascular biotechnology company, which engages in the development of therapeutics for the treatment of heart failure and cardiovascular diseases. The company was founded by Michael E. Mendelsohn in 2017 and is headquartered in Boston, MA. | Directeur/Membre du Conseil | 01/01/2019 |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | 01/01/2016 |
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Directeur Général | 01/04/2014 |
| PFIZER, INC. | Corporate Officer/Principal | 01/02/2012 |
Arriva Pharmaceuticals, Inc.
 Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Directeur/Membre du Conseil | 19/01/2011 |
Formation de Edward Mascioli
| Massachusetts Institute of Technology | Graduate Degree |
| Brandeis University | Undergraduate Degree |
| University of Massachusetts | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 18 |
|---|---|
PAREXEL International Corp.
 PAREXEL International Corp. Miscellaneous Commercial ServicesCommercial Services PAREXEL International Corp. provides biopharmaceutical services. It offers clinical research and logistics, medical communications, consulting, commercialization and advanced technology products and services for pharmaceutical, biotechnology and medical device industries. The company was founded in 1983 and is headquartered in Newton, MA. | Commercial Services |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Elixir Pharmaceuticals, Inc.
 Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA. | Miscellaneous |
Oxagen Ltd.
 Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Health Technology |
Peptimmune, Inc.
 Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Gilead Connecticut, Inc.
 Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA. | Health Technology |
Mindset BioPharmaceuticals Ltd.
Mindset BioPharmaceuticals Ltd. Medical/Nursing ServicesHealth Services Mindset BioPharmaceuticals Ltd. develops disease modifying therapies. It specializes in molecular neuropharmacology, behavioral science, clinical neurology, drug delivery, and biopharmaceutical development. The company was founded by Daniel G. Chain in February 1997 and is headquartered in Jerusalem, Israel. | Health Services |
Affinium Pharmaceuticals Ltd.
Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
Deaconess Hospital (Oklahoma)
 Deaconess Hospital (Oklahoma) Hospital/Nursing ManagementHealth Services Part of Community Health Systems, Inc., Deaconess Hospital is a 313-bed hospital based in Oklahoma City, OK. The hospital provides medical services to patients in the area. | Health Services |
Sancilio & Co., Inc.
 Sancilio & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL. | Commercial Services |
Karos Pharmaceuticals, Inc.
 Karos Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Karos Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The firm focuses on bone related, pulmonary arterial hypertension and other orphan diseases. The company was founded in 2009 and is headquartered in New Haven, CT. | Health Technology |
Sancilio Pharmaceuticals Co., Inc.
 Sancilio Pharmaceuticals Co., Inc. Miscellaneous Commercial ServicesCommercial Services Sancilio Pharmaceuticals Co. engaged in the development and manufacture of pharmaceutical products. Its product platform, advanced lipid technologies, focuses on the treatment of diseases and disorders related to lipids such as sickle cell, short bowel, severe hypertriglyceridemia and non-alcoholic fatty liver. The company was founded by Frederick Sancilio in October 2004 and was headquartered in Riviera Beach, FL. | Commercial Services |
| Dapis Capital LLC | |
Cardurion Pharmaceuticals LLC
Cardurion Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardurion Pharmaceuticals LLC is a cardiovascular biotechnology company, which engages in the development of therapeutics for the treatment of heart failure and cardiovascular diseases. The company was founded by Michael E. Mendelsohn in 2017 and is headquartered in Boston, MA. | Health Technology |
Matrivax Research & Development Corp.
Matrivax Research & Development Corp. BiotechnologyHealth Technology Matrivax Research & Development Corp. is developing human vaccines for the prevention and treatment of life-threatening bacterial diseases. Its pipeline includes two vaccine candidates implementing proprietary streptococcus pneumoniae and clostridium difficile protective antigens. The company was founded in October 2007 and is headquartered in Boston, MA. | Health Technology |